IronNet spikes 37% after announcing joining Microsoft Intelligent Security Assoc » 15:1210/2710/27/21
IronNet (IRNT) jumped 37%…
IronNet Inc (Class A Stock) call volume above normal and directionally bullish » 10:4510/2710/27/21
Bullish option flow…
Usana backs FY21 EPS view of $5.80-$6.00, two estimates $5.93 » 16:2010/2610/26/21
Backs FY21 revenue view…
Backs FY21 revenue view of $1.18B-$1.20B, two estimates $1.19B
Usana reports Q3 EPS $1.36, two estimates $1.30 » 16:1910/2610/26/21
Reports Q3 revenue…
Reports Q3 revenue $274.4M, two estimates $268.06M. "As we indicated a month ago, the operating environment remains challenging across several of our key markets due, in great part, to disruptions and lockdowns related to the COVID-19 pandemic," said Kevin Guest, CEO. "Additionally, the year-over-year comparison was difficult given the significant short-term sales program that we offered in the prior year quarter. Notwithstanding these challenges, we continue to execute our growth strategy, which is centered on generating sustainable customer growth. We made progress on several strategic initiatives during the quarter. Enhancing the overall shopping experience for our customers remains a high priority, and to that end, we rolled out additional features and functionality within our China shopping app, as well as a new web-based shopping cart in China. Although our introduction of certain new products has been delayed until 2022, we are actively engaged in bringing new and innovative products to market. Overall, we remain confident that the successful execution of our strategy will deliver long-term, sustainable growth."
Diamondback Energy price target raised to $147 from $127 at Mizuho » 06:4510/2610/26/21
Mizuho analyst Vincent…
Mizuho analyst Vincent Lovaglio raised the firm's price target on Diamondback Energy to $147 from $127 and keeps a Buy rating on the shares. The analyst increased price targets across the oil exploration and production group ahead of Q3 earnings citing increasing confidence in a second half of 2022 call on U.S. unconventional oil growth. Energy is poised to outperform and exploration and production is positioned to lead, Lovaglio tells investors in a research note.
Agenus price target lowered to $11 from $12 at B. Riley » 08:1110/2510/25/21
B. Riley analyst Mayank…
B. Riley analyst Mayank Mamtani lowered the firm's price target on Agenus to $11 from $12 and reiterates a Buy rating on the shares. The company unexpectedly announced the decision to voluntarily withdraw the application for its anti PD-1 drug candidate, balstilimab, ahead of the original December 16 action date date at the FDA's recommendation following agency granting full approval to Merck's Keytruda four months earlier than its target action date, Mamtani tells investors in a research note. The analyst views the update as disappointing.
Largest borrow rate increases among liquid names » 08:4510/2210/22/21
DNA, HOOD, SKIN, RKLB, CIFR, OPAD, MVST, SPIR, LICY, DOLE
Latest data shows the…
Latest data shows the largest indicative borrow rate increases among liquid option names include: (DNA) 162.59% +53.05, Robinhood Markets (HOOD) 179.03% +12.42, Beauth Health Company (SKIN) 11.00% +10.67, Rocket Lab USA (RKLB) 46.22% +9.10, (CIFR) 145.69% +4.39, (OPAD) 69.10% +2.42, Microvast Holdings (MVST) 120.00% +2.02, Spire Global (SPIR) 65.92% +1.39, Li Cycle Holdings Corp (LICY) 29.86% +1.02, and (DOLE) 1.38% +0.50.
Agenus withdraws BLA for balstilimab, decides to discontinue BRAVA trial » 08:0510/2210/22/21
Agenus announced a…
Agenus announced a strategic decision to withdraw its Biologics License Application for balstilimab, its PD-1 inhibitor. The decision to withdraw the BLA does not change the development plans for balstilimab combinations. Following the full approval of pembrolizumab, announced four months earlier than the FDA goal date, the U.S. Food and Drug Administration no longer considered it appropriate to review the BLA for accelerated approval and recommended Agenus withdraw. The BLA submission for balstilimab received Fast Track and Priority Review designation from the FDA, with a target action date of December 16, 2021. As part of the BLA review process, Agenus completed 3 FDA inspections with no cited issues, concerns, or Form-483s. As previously reported, in the largest single-arm trial to date in this population, balstilimab demonstrated objective responses in both PD-L1 positive and negative patients, with an objective response rate of 20% and 8% respectively. Pembrolizumab has demonstrated an ORR of 14% and 0% in PD-L1 positive and negative patients respectively, which led to its accelerated approval in 2018. Balstilimab has shown superior killing of PD-L1 negative tumors compared to other anti PD-1 therapies, including pembrolizumab, suggesting a broader mechanism consistent with balstilimab's clinical activity in both PD-L1 positive and negative cervical cancer2. Concurrent with the withdrawal, Agenus will discontinue its ongoing confirmatory trial in this population, which is expected to reduce R&D expenses by over $100M. However, given the clinical benefit demonstrated by balstilimab, Agenus plans to launch expanded access programs to give patients and doctors access to balstilimab in several countries, including the US, pending regulatory processes.
Rattler Midstream to acquire certain assets from Diamondback Energy for $160M » 16:1110/2110/21/21
Rattler Midstream (RTLR)…
Rattler Midstream (RTLR) announced that Rattler Midstream Operating entered into a definitive purchase agreement to acquire certain water midstream assets from subsidiaries of Diamondback Energy (FANG) for $160M in cash in a drop down transaction. The assets subject to the drop down consist primarily of produced water gathering and disposal systems, produced water recycling facilities, and sourced water gathering and storage assets acquired by Diamondback through transactions with QEP Resources, Inc. and Guidon Operating and certain of its affiliates in early 2021. Additionally, Rattler and Diamondback have mutually agreed to amend commercial agreements covering the produced water gathering and disposal and sourced water gathering services between Rattler and Diamondback to add certain Diamondback leasehold acreage to the Rattler dedication. Rattler intends to fund the transaction, expected to close in Q4, through cash on hand and borrowings under its revolving credit facility.
Diamondback Energy price target raised to $131 from $112 at Piper Sandler » 06:0510/2110/21/21
Piper Sandler analyst…
Piper Sandler analyst Mark Lear raised the firm's price target on Diamondback Energy to $131 from $112 and keeps an Overweight rating on the shares into the Q3 reporting season. While 2021 was largely anticipated to be a balance sheet repair year for domestic exploration and production companies, stronger than expected commodity prices have pulled forward shareholder return plans, Lear tells investors in a research note. The group is broadly anticipated to reduce capex and execute maintenance budgets in 2022, "which ultimately should bring investors back to the sector," says the analyst.